Friday, January 27, 2023
CytomX Therapeutics, Inc today announced that it has achieved a clinical candidate milestone under its TCB agreement with Astellas. The clinical candidate is the first Probody® TCB molecule to progress in the collaboration and will trigger a $5 million dollar milestone payment to CytomX. CytomX and Astellas are also collaborating on other conditionally activated TCB programmes with CytomX eligible to receive future preclinical, clinical and commercial milestones.
Localising T-cell activity to the tumour microenvironment could result in important breakthroughs for patients, and the Probody® platform has potential to address this challenge.
CytomX partnership with Astellas will continue in advancing novel TCBs towards the clinic to make a significant contribution in bringing the power of T-cell engaging therapies to a broader set of patients with cancer.
